Concept: PARP inhibition in cancer therapy
Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2
Resistance mechanisms to PARP inhibitor therapy in BRCA-mutant breast cancer
CTF18-RFC structure reveals how it binds PCNA
Molecular structure reveals how a key protein complex loads DNA replication machinery
